The agenda for the general meeting was as follows:

1. ELECTION OF CHAIRMAN OF THE MEETING
   1. Mikkel Rostock-Jensen was elected chairman of the meeting. The chairman of the meeting ascertained that none of the shareholders objected to the legality of the annual general meeting and announced that the annual general meeting had been duly convened and was legal and competent in terms of all items on the agenda. The chairman of the general meeting then informed that based on postal votes and proxies duly received prior to the general meeting a solid support of all proposals on the agenda had been secured in advance of the meeting.

2. REPORT ON THE ACTIVITIES OF THE COMPANY IN THE PAST FINANCIAL YEAR
   1. The report on the Company’s activities in 2024 was noted by the general meeting.

3. PRESENTATION OF THE ANNUAL REPORT WITH AUDITORS’ REPORT FOR ADOPTION
   1. The general meeting unanimously adopted the audited annual report with auditors’ report for 2024.

4. RESOLUTION ON COVERING OF LOSSES IN ACCORDANCE WITH THE ADOPTED ANNUAL REPORT
   1. The general meeting unanimously resolved that the consolidated loss for the financial year 2024 of tDKK 19,053 is carried forward to the next financial year in accordance with the adopted annual report.

5. ELECTION OF MEMBERS TO THE BOARD OF DIRECTORS
   1. The general meeting unanimously decided to re-elect Martin Olin, Charlotte Videbæk, Flemming Steen Jensen and Rachel Curtis Gravesen. For the purpose of these minutes, it is noted that the board of directors subsequently elected Martin Olin as chairman of the board.

6. ELECTION OF AUDITOR
   1. The general meeting unanimously re-elected PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab, CVR no. 41293055, as the Company’s auditor

7. PROPOSALS FROM THE BOARD OF DIRECTORS AND SHAREHOLDERS
   None

The chairman of the general meeting announced that all the agenda items had been discussed and announced that the annual general meeting had come to an end.

As chairman of the annual general meeting:

Mikkel Rostock-Jensen

For more information about Cessatech, please contact:
Jes Trygved, CEO
Phone: +45 9387 2309
E-mail: jes.trygved@cessatech.com
www.cessatech.com

About Cessatech
Cessatech A/S is a Danish pharmaceutical company committed to developing and commercializing evidence-based and innovative medicines for children for the treatment of paediatric acute pain. Its lead asset (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children. The advantages include needle-free administration, easy administration, a fast-acting therapeutic effect, and being medically approved for children. CT001 is at its pivotal stage of clinical development, and CT002 is at the early development phase.